Mitsubishi Tanabe Gains Premium Prices For Fingolimod And Telaprevir
This article was originally published in PharmAsia News
Executive Summary
Japan's Chuikyo rewarded the company with better-than-expected NHI listings, but can Mitsubishi Tanabe's sales force shortages help fill demand?
You may also be interested in...
Mitsubishi Tanabe Sees Open Road With Telaprevir Approval And Merck's Boceprevir Discontinued In Japan
TOKYO - Mitsubishi Tanabe Pharma Corp. received a double dose of good news Sept. 26, leading a list of drugs that received marketing approval from Japan's Ministry of Health, Labor and Welfare with in-licensed protease inhibitor telaprevir and oral multiple sclerosis therapy fingolimod
Avastin Recommended For Breast Cancer Approval In Japan; Telaprevir Leads List Of Unanimous Recommendations
TOKYO - Telaprevir and a metastatic breast cancer indication for Avastin (bevacizumab) were among the blanket recommendations for approval by the Second Subcommittee on New Drugs of Japan's Ministry of Health, Labor and Welfare announced late in the day Aug. 25. Avastin's recommendation came just a few weeks after the subcommittee had expressed doubts about the drug's efficacy
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?